BriaCell Therapeutics (BCTX) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025.
The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell regimen or physician's choice, with a subset of 50 patients receiving Bria-IMT monotherapy, the company said.
BriaCell Therapeutics shares rose more than 6% in recent trading.
Price: 0.95, Change: +0.06, Percent Change: +6.22
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。